#Novamind kat.cr update
#Novamind kat.cr trial

Novamind's CCR is specialized in hosting clinical trials for psychedelic medicines and other innovative therapies. 'We need more innovation in this field and I'm hopeful to see compounds like KarXT that have new ways of acting on the brain and the potential for improved efficacy and side effect profiles.'

Reid Robison, Novamind's Chief Medical Officer and Principal Investigator at CCR. 'Current antipsychotic drugs fall short for too many individuals with schizophrenia, leaving them with either debilitating symptoms or serious side effects like sedation, weight gain and involuntary movements,' said Dr. The phase III study titled, 'An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients with Schizophrenia (EMERGENT-5)' will evaluate the investigational therapy KarXT for the treatment of schizophrenia, a serious and potentially disabling condition affecting approximately 20 million people worldwide.1 ('Karuna'), a clinical-stage neuroscience biopharmaceutical company.

#Novamind kat.cr trial

(CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ('Novamind' or the 'Company'), a leading mental health company specialized in psychedelic medicine, is pleased to announce that its wholly owned subsidiary, Cedar Clinical Research ('CCR') has been selected as a research site for a clinical trial sponsored by Karuna Therapeutics, Inc. TORONTO, ON / ACCESSWIRE / Septem/ Novamind Inc.

#Novamind kat.cr update

The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable laws.Cedar Clinical Research to Host Phase III Trial for Investigational Therapy for Schizophrenia Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The reader is cautioned not to place undue reliance on any forward-looking information. Important factors that could cause actual results to differ materially from the Company's expectations including the risks detailed from time to time in the Company's public disclosure. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. All statements other than statements of historical fact included in this release are forward-looking statements that involve risks and uncertainties. This news release contains forward-looking statements. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit novamind.ca. Both Cedar Psychiatry and Cedar Clinical Research are wholly owned subsidiaries of Novamind. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics and clinical research sites. The Company expects to file the Required Filings today, November 4, 2021.

If the cease trade order is revoked, the Company expects trading of the Company's common shares on the CSE to resume. If the Company files the Required Filings within 90 days of the date of the cease trade order, the filing of the Required Filings constitutes the Company's application to revoke the cease trade order.

The delay in the filing of the Required Filings was due to the Company's auditor requiring more time to complete its audit procedures related to the Company's annual financial statements for the year ended June 30, 2021.As a result of the cease trade order, the Company's common shares are expected to be suspended from trading on the Canadian Securities Exchange ('CSE').

certification of the foregoing filings as required by National instrument 52-109 Certification of Disclosure in Issuers' Annual and Interim Filings.management's discussion and analysis relating to the audited financial statements for the year ended Jand.audited annual financial statements for the year ended J.(CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ('Novamind' or the 'Company'), a leading mental health company specialized in psychedelic medicine, today announced that it is the subject of a failure-to-file cease trade order issued by the Ontario Securities Commission on Novemas a result of the Company's failure to timely file the following continuous disclosure documents (collectively, the ' Required Filings') by Octo(the ' Filing Deadline'): TORONTO, ON / ACCESSWIRE / Novem/ Novamind Inc.